Carl Icahn shares common ground with the FTC, which argued that Illumina’s acquisition of cancer test developer Grail would stifle competition and innovation.
Illumina told shareholders that Carl Icahn’s board nominees would “threaten the progress” of the biotech company’s core business.
Carl Icahn claims Illumina directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of Grail
Nothing, the hardware venture from OnePlus co-founder Carl Pei, is in early talks with American carriers to launch a phone in the country.
Veteran activist Carl Icahn took an 8.5% stake in Crown Holdings. There are a few opportunities to build shareholder value.
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}
){kind=link}